PolyNovo (ASX:PNV) logged a total monthly revenue of AU$12.4 million in March, up nearly 49% compared with the same time in 2024, according to a Wednesday filing with the Australian bourse.
Commercial sales climbed over 71% to AU$11.9 million. This was buoyed by record monthly sales of AU$9.3 million in the US, a 93% increase on the year-ago period.
Sales in the year to March surged 31% to AU$84.4 million.
In the same filing, the company said it has roughly 10 months of inventory on hand in the US and does not expect a material impact from the US tariffs based on preliminary assessment.
The medical device company's shares were down 8% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。